Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records β€” linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review claims



    Explore by Goal












     Quick Explanation


    BGPT evidence-based author strength check (based only on provided paper records)
    • Strength signals: mechanistic molecular/genome-architecture work with fairly strong experimental integration in papers like Dory (chromatin tracing differential analysis) and the CTCF boundary orientation study (, ).
    • Red-flag signals: at least one explicitly labeled retracted article in the provided record set ().



     Long Explanation


    Author Review: Zhaoxia Wang
    BGPT epistemic stance
    Evidence is limited to the papers/DOIs and excerpts you provided; where details are missing, I mark uncertainty.
    1) What can be concluded from the provided records
    • The provided dataset contains multiple biology-adjacent papers (cancer genomics/3D genome; NSCLC lncRNAs; microglial neuroinflammation; rare myopathy genetics; etc.), but the evidence is incomplete (no full reference list, no full methods/replicate counts for all papers, and OpenAlex lookup timed out).
    • At least one provided record is explicitly labeled retracted, which is a strong negative signal for scientific reliability ().
    • Two provided records (Dory; outward-oriented CTCF boundary sites) include fairly sophisticated experimental + computational frameworks with validation/robustness elements and/or genome topology assays, which is a positive signal (, ).
    2) Evidence visualization (quality + novelty + reproducibility signals from provided excerpts)
    Note: the numeric β€œscores” shown below come from the BGPT-provided extraction fields, not from external evaluation datasets.
    The outward-oriented CTCF boundary paper is the strongest positive signal in this extracted subset due to multi-modal genome topology + chromatin state + perturbation design ().
    3) Mechanistic strengths and biological plausibility (paper-by-paper, only from your excerpts)
    3.1 CTCF β€œoutward-oriented sites” and TAD insulation
    The study tests causal effects of deleting specific CTCF binding-site elements and enhancer segments on intra-TAD promoter–enhancer contacts and target gene expression, using CRISPR editing plus 4C/Hi-C, ChIP-seq, ATAC-seq, RNA-seq, and additional assays ().
    Why this is scientifically strong (from excerpted details): causal perturbations + orthogonal readouts (expression + accessibility/state + 3D contacts) reduce pure correlation risk.
    What remains uncertain / possible limitations: the provided excerpt notes small sample sizes in some deletion lines and locus-focused testing; generalization across boundary contexts is not proven ().
    3.2 Dory: differential analysis for chromatin tracing distances
    Dory is presented as a scalable R-based differential method that computes Euclidean distances between all pairs of probed loci inside each chromatin trace and compares distance-vector distributions across two conditions via unpaired Wilcoxon rank-sum tests; it defines DiffScore matrices (with signed directionality) and identifies β€œdifferential region pairs” without reconstructing full chromatin structures ().
    Blind spots called out by the provided excerpt: the approach assumes independence between genomic region pairs (and does not model intrachromosomal interactions), resolution is constrained by experimental design, and missing-data handling/imputation is not integrated to avoid bias ().
    3.3 CASC9 lncRNA β†’ EZH2 β†’ DUSP1 and gefitinib resistance (NSCLC)
    The excerpt reports CASC9 upregulation in gefitinib-resistant NSCLC, with CASC9 knockdown increasing gefitinib sensitivity; mechanistically, CASC9 is said to bind EZH2 and repress DUSP1 by reducing H3K27 trimethylation at the DUSP1 promoter, affecting ERK signaling and drug response. In vivo xenografts using PC9/GR cells are described ().
    Key limitations (from your excerpt): the excerpt notes reliance on PC9/GR and immunodeficient xenografts, modest patient sample size, and the need for validation across additional subtypes/cohorts; off-target effects of siRNA/ASO are also possible ().
    3.4 Retracted USP4 study (microglia OGD/R; TRAF6–NF-ΞΊB)
    The provided record is explicitly labeled as a Retracted Article and describes USP4 overexpression attenuating microglial activation and neurotoxicity in an OGD/R primary cell setup, via TRAF6–NF-ΞΊB. Because it is retracted, it should not be treated as reliable evidence for the claimed mechanism ().
    Most important critique point: the reliability of this specific mechanistic pathway claim cannot be upheld from a retracted publication; any downstream citations should be checked against retraction notices and subsequent corroborating studies (not provided here).
    3.5 Clinical genetics: Laing distal myopathy; MYH7 in-frame deletions
    The excerpt describes a small retrospective Chinese cohort (n=6) with MYH7 mutations in all patients, where in-frame deletions are reported as common in this set, alongside MRI/pathology characterization and sleep apnea in some individuals. It explicitly states limited generalizability and absence of functional assays ().
    4) Integrated critique: what the author’s record suggests (and what it cannot prove)
    • Possible strength: ability to work across computational genomics (3D genome/chromatin tracing differential analysis) and mechanism-oriented chromatin regulation perturbations (CTCF boundary orientations), which often requires cross-disciplinary rigor (, ).
    • Major reliability concern: a retracted publication in the provided set is an unambiguous negative signal for scientific dependability and/or reporting integrity ().
    • Generalizability caution: multiple excerpts explicitly note constraints such as small sample sizes, locus-specific focus, and model-system dependence (PC9/GR, neonatal rat primary cells, single-center clinical cohort). These limitations constrain how confidently one can generalize biological claims beyond the studied systems (, , ).
    What would change this assessment (disproving information): (i) confirmation that the retracted record is retracted for reasons consistent with honest error and that independent follow-ups corroborate the broader claims; (ii) additional high-quality, independently replicated mechanistic work without retractions; (iii) transparent data/code availability and robust cross-model validation across multiple systems.
    5) Optional follow-up paths (BGPT)
    Because your supplied input doesn’t include full bibliographic metadata for every record (and OpenAlex timed out), BGPT would need to re-index additional papers to produce a stronger, citation-metric-driven critique.


    Feedback:    

    Updated: April 17, 2026

     Top Data Sources ExportMCP


     Hypothesis Graveyard


    Generalizing CTCF orientation β†’ insulation universally across all TADs: likely too strong because boundary contexts are tissue- and locus-dependent, and the excerpt itself frames generalization as uncertain ().

     Science Art


    Author Review: Zhaoxia Wang Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending